Eli Lilly and Company engages in the discovery, development, manufacture, and sale of products in pharmaceutical products business segment. The Сompany also conducts research to find products to treat diseases in animals and to increase the efficiency of animal food production. Its prodcuts, include Zyprexa, for the treatment of schizophrenia, acute mixed or manic episodes associated with bipolar I disorder, and bipolar maintenance; Cymbalta, for the treatment of major depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, and in the United States for the management of fibromyalgia; Strattera, for the treatment of attention-deficit hyperactivity disorder in children, adolescents and adults; Prozac, for the treatment of major depressive disorder, obsessive-compulsive disorder, bulimia nervosa and panic disorder; and Symbyax, for the treatment of bipolar depression. Endocrinology products, include: Humalog, Humalog Mix 75/25, and Humalog Mix 50/50tm, for the treatment of diabetes; Humulin, for the treatment of diabetes; Byetta, for the treatment of type 2 diabetes; Actos, for the treatment of type 2 diabetes; Evista, for the prevention and treatment of osteoporosis in postmenopausal women and for the reduction of the risk of invasive breast cancer in postmenopausal women with osteoporosis and postmenopausal women at high risk for invasive breast cancer; Forteo, for the treatment of osteoporosis in postmenopausal women and men at high risk for fracture; and Humatrope, for the treatment of human growth hormone deficiency and idiopathic short stature.

Company Growth (employees)
Indianapolis, US
Size (employees)
41,975 (est)
Eli Lilly was founded in 1876 and is headquartered in Indianapolis, US

Key People/Management at Eli Lilly

David Ricks

David Ricks

Chairman and Chief Executive Officer
Susan Mahony

Susan Mahony

Senior Vice President and President, Lilly Oncology
Stephen Fry

Stephen Fry

Senior Vice President, Human Resources and Diversity
Melissa Barnes

Melissa Barnes

Senior Vice President, Enterprise Risk Management, and Chief Ethics and Compliance Officer
Enrique Conterno

Enrique Conterno

Senior Vice President and President, Lilly Diabetes; President, Lilly USA
Alfonso Zulueta

Alfonso Zulueta

Senior Vice President and President, Lilly International
Johna Norton

Johna Norton

Senior Vice President, Global Quality
Myles O'Neill

Myles O'Neill

Senior Vice President and President, Manufacturing Operations
Leigh Pusey

Leigh Pusey

Senior Vice President, Corporate Affairs and Communications
Aarti Shah

Aarti Shah

Senior Vice President, Information Technology, and Chief Information Officer
Christi Shaw

Christi Shaw

Senior Vice President and President, Lilly Bio-Medicines
Jeffrey Simmons

Jeffrey Simmons

Senior Vice President and President
Joshua Smiley

Joshua Smiley

Senior Vice President and Chief Financial Officer

Eli Lilly Office Locations

Eli Lilly has offices in Indianapolis, Chuo Ward, Wien, Melrose Park and in 141 other locations
Indianapolis, US (HQ)
Lilly Corporate Center
Melrose Park, AU
112 Wharf Rd
Wien, AT
8-10 Kölblgasse
Toronto, CA
3650 Danforth Ave
Chuo Ward, JP
Sannomiya Plaza Building 7-1-5 Isogami-dori Chuo-ku, Kobe
Windlesham, GB
Erl Wood Manor Sunninghill Road
Show all (196)

Eli Lilly Financials and Metrics

Eli Lilly Financials

Eli Lilly's revenue was reported to be $21.2 b in FY, 2016 which is a 6% increase from the previous period.

Revenue (FY, 2016)

21.2 b

Revenue growth (FY, 2015 - FY, 2016), %


Gross profit (FY, 2016)

15.6 b

Gross profit margin (FY, 2016), %


Net income (FY, 2016)

2.7 b

Market capitalization (16-Feb-2018)

83.4 b

Cash (31-Dec-2016)

4.6 b


87.2 b
Eli Lilly's current market capitalization is $83.4 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016


23.1 b19.6 b20 b21.2 b

Revenue growth, %


Cost of goods sold

4.9 b4.9 b5 b5.7 b

Gross profit

18.2 b14.7 b14.9 b15.6 b
USDFY, 2013FY, 2014FY, 2015FY, 2016


3.8 b3.9 b3.7 b4.6 b

Accounts Receivable

588.4 m566.7 m558.6 m736.9 m


2.9 b2.7 b3.4 b3.6 b

Current Assets

13.1 b12.2 b12.6 b15.1 b
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

4.7 b2.4 b2.4 b2.7 b

Cash From Operating Activities

5.7 b4.4 b2.8 b4.9 b

Purchases of PP&E

(1 b)(1.2 b)(1.1 b)(1 b)

Cash From Investing Activities

(2.1 b)(3.9 b)26.8 m(3.1 b)
USDY, 2016


18 x


511.3 k


0.6 x


0.2 x

Financial Leverage

2.8 x
Show all financial metrics

Eli Lilly Operating Metrics

FY, 2013FY, 2014FY, 2015FY, 2016

Projects in R&D Pipeline


Phase III Trials

Show all operating metrics

Eli Lilly Acquisitions / Subsidiaries

Acquired CompanyDateDeal Size
CoLucid PharmaceuticalsJanuary 18, 2017$960 m
Novartis Animal HealthApril 22, 2014$5.4 b
Avid RadiopharmaceuticalsNovember 08, 2010$800 m
Alnara PharmaceuticalsJuly 02, 2010$280 m
Imclone SystemsOctober 06, 2008$6.5 b

Eli Lilly Market Value History

Eli Lilly Median Salaries

Source: 117 public H-1B filings from Eli Lilly

Eli Lilly's Web-traffic and Trends

Eli Lilly Online and Social Media Presence

Eli Lilly News and Updates

Eli Lilly, sporting a lower tax rate, scouts smaller deals in immunology, cancer

Eli Lilly has steered away from megadeals, and a big influx of cash from U.S. tax reform won’t change that. Darren Carroll, SVP of business development, thinks behemoth buys will get the biggest boost as companies bring overseas earnings home, but “those deals, frankly, we don’t believe are very hel…

Eli Lilly builds $23B-plus sales forecast on diabetes, cancer launches

Eli Lilly is betting that its new drugs will kick off an era of growth, but the company will have to contend with a tough environment in diabetes and a hefty patent expiration as it aims for 2018 revenue of $23 billion to $23.5 billion.

Eli Lilly counts up 2,300 early retirements in $500M cost-cutting drive

Eli Lilly has persuaded 2,300 employees to take early retirement as part of a companywide streamlining designed to save $500 million. With those settled, the company says it's "on track to achieve" the 3,500 job cuts it outlined in September, with some facilities closing entirely.

As Eli Lilly moves some marketing in-house, should ad agencies brace for fallout?

Eli Lilly is moving to a new marketing model as part of its push to manage expenses, but what does that mean for its advertising and marketing agency partners? So far, no one is saying exactly, but it almost certainly means less work as Lilly looks to bring more of the traditional agency of record s…

U.K. Supreme Court hands Eli Lilly big win in Alimta EU patent battle

The U.K. Supreme Court has handed Eli Lilly a huge patent victory for its cancer drug Alimta in a battle with Actavis, protecting some European sales of the blockbuster for another four years. It also represents a stunning loss for Actavis, now owned by Teva, which launched its generic several years…
Show more

Eli Lilly Company Life and Culture

You may also be interested in